Homesecondary progressive multiple sclerosis

  • SPMS patients have higher cognitive decline than RRMS patients, study reports

    • April 17, 2018
    • Posted by: PharmaScroll
    • Category:
    No Comments
    read more

  • Roche Acquires regenerative MS therapy program focused on remyelination

    • April 5, 2018
    • Posted by: PharmaScroll
    • Category:
    No Comments
    read more

  • NATCO launches generic version of Aubagio for MS in INDIA

    • April 5, 2018
    • Posted by: PharmaScroll
    • Category:
    No Comments
    read more

  • First patient enrolled in Ph 3 Trial of ADS-5102 in MS Patients with Walking Impairment

    • April 5, 2018
    • Posted by: PharmaScroll
    • Category:
    No Comments
    read more

  • Novel PET imaging agent to assess treatments for neurological diseases

    • April 4, 2018
    • Posted by: PharmaScroll
    • Category:
    No Comments
    read more

  • FLX-787 in Multiple Sclerosis displays positive Phase 2 Topline results

    • March 28, 2018
    • Posted by: PharmaScroll
    • Category:
    No Comments
    read more

  • Secondary Progressive MS – Pharmascroll Report predicts increase in market activity in next 5-10 years

    • March 26, 2018
    • Posted by: PharmaScroll
    • Category:
    No Comments

    Expected launch of Siponimod and a strong pipeline in SPMS indicates a strong SPMS focus. SPMS- Detailed overview provides an overview of SPMS in detail, highlights the SPMS epidemiology, elaborates on the drugs prescribed and expected to be prescribed along with the sales and patient numbers forecast.

    read more

  • Siponimod significantly improves patient outcomes in SPMS, as per latest study

    • March 23, 2018
    • Posted by: PharmaScroll
    • Category:
    No Comments
    read more